6.2.2026
SL Insight Newsletter #18
Working group "Life Sciences Location" as a signal to MFN
Marcel Boller
On January 13, 2026, the federal government set up a working group on "Life Sciences Location" with a mandate to report by the end of 2026. The composition of the group is striking: in addition to the administration, including the FOPH, scienceindustries, Interpharma, and vips are also at the table. This sends an institutional signal: MFN/GENEROUS is not being treated as a purely price-related issue, but is being elevated to a location and supply perspective.
What should we make of the working group?
MFN is being "raised" politically: away from case-by-case pricing logic and toward cross-cutting issues (innovation, supply, location). Therefore, no immediate pricing decisions are to be expected, but rather a clarification of the guidelines. The focus is on integrating MFN into the Swiss remuneration logic and understanding the role of supply security, evidence, and innovation. We can look forward to the first milestones in this process.
